NVCR News and Press, NovoCure Limited From 07/30/20

NovoCure Limited (NVCR) Q2 2020 Results Conference Call July 30, 2020 08:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chief Fi...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q2 earnings Read more ...

Quarterly net revenues of $115.9 million, representing 34 percent growth versus the second quarter 2019 and 14 percent growth versus the first quarter 2020 Financial strength allows for continued investments in clinical and product innovation Novocure (NASDAQ: NVCR) today reported...

Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Trea...

XBiotech makes a crucial breakthrough in True Human antibodies Development XBiotech Inc. (XBIT) reported that it has made an important breakthrough in the development of True Human antibodies, novel inflammation countering mechanism. This new type of antibody seeks to replace previous-gene...

In this episode of Industry Focus: Wildcard , Jason Moser chats with Motley Fool analyst Brian Feroldi about three promising healthcare stocks that he personally bought. Discover their innovative products, which facilitate easy and quick diagnosis of peripheral artery disease -- plus, a "medi...

Novocure ( NVCR +5.6% ) has enrolled first patient in its Phase 2 pivotal (EF-33) trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma (GBM). More news on: NovoCure Limited, Healthcare stocks news, Read more .....

EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor T...

Brief investment pitch This disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016 (when it was trading at $7.76/share). I wrote the title in my initiation article as ' NovoC ure's TTFields Therapy Could Become The Standard Adjunct Therap...

The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...